stockrow
Friday 6 November 2026
Export CBLL’s income statement to Excel — free account
CeriBell, Inc.
CBLL Healthcare Medical Devices
CeriBell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $89.1 million, up 36.1% from fiscal 2024.
- Revenue
- +29.9%
- EPS
- −49.9%
- Free cash flow
- −19.7%
- Total debt
- +1.29%
Quarter to September 2026, against a year earlier
26.52
0.51
+1.96%
Follow CBLL
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 45 | 65 | 89 | 109 | +40.3% | 116 | 147 | 188 | +28.2% | |
| Gross margin, % | — | — | — | — | — | — | — | 84.38 | 86.72 | 87.89 | 89.26 | +3.5 pt | ||||||
| EBT | — | — | — | — | — | — | — | (29) | (40) | (53) | (74) | +34.7% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | (65.13) | (61.82) | (59.97) | (67.96) | +5.2 pt | ||||||
| Net income | — | — | — | — | — | — | — | (29) | (40) | (53) | (74) | +34.6% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 8.53 | 5.48 | 2.44 | 2.82 | (46.5%) | |||||
| Earnings | — | — | — | — | — | — | — | (5.56) | (3.39) | (1.46) | (1.94) | (48.7%) | ||||||
| Cash flow | — | — | — | — | — | — | — | (5.50) | (2.93) | (1.12) | (1.45) | (54.9%) | ||||||
| Capex | — | — | — | — | — | — | — | (0.33) | (0.13) | (0.04) | (0.06) | (64.6%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (5.83) | (3.07) | (1.16) | (1.52) | (55.4%) | ||||||
| Book value | — | — | — | — | — | — | — | (21.16) | 16.00 | 4.25 | 3.05 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 5 | 12 | 37 | 38 | +162.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 2.41 | 4.73 | 9.00 | 9.21 | 5.4 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 1.62 | 5.16 | 8.52 | 2.3 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 2.50 | 2.05 | 7.43 | 8.31 | 4.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (4.47) | (3.67) | (15.64) | (15.48) | (7.9) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (29) | (35) | (41) | (56) | +18.3% | |||||
| Capex | — | — | — | — | — | — | — | (2) | (2) | (2) | (2) | (7.1%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (31) | (37) | (42) | (58) | +17.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 30 | 204 | 168 | 129 | +134.9% | |||||
| Net debt | — | — | — | — | — | — | — | (34) | (175) | (139) | (97) | +101.1% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | (112) | 191 | 155 | 118 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (28.46) | (25.36) | (41.52) | (25.4) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | (151.76) | (229.77) | (236.27) | (229.8) pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | (102.53) | (30.83) | (52.47) | (30.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 240 | 281 | 327 | — | +16.7% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.19 | 0.23 | 0.27 | — | +20.2% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
CeriBell, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics Corporation | $1.2B | — (loss-making) | — (loss-making) | +17.96% (above 0%: growing) | n/m | −1.57% (below 0%: shrinking) | 66.28% | (27.85%) | Compare |
| IART Integra LifeSciences Holdings Corporation | $1.1B | 83.0× | 26.0× | +2.27% (above 0%: growing) | n/m | +232.94% (above 0%: growing) | 51.04% | 4.60% | Compare |
| SIBN SiBone | $1.1B | — (loss-making) | — (loss-making) | +14.49% (above 0%: growing) | n/m | +31.13% (above 0%: growing) | 79.29% | (7.81%) | Compare |
| IRMD iRadimed Corporation | $1.1B | 44.9× | 39.6× | +14.15% (above 0%: growing) | +15.91% (above 0%: growing) | +18.58% (above 0%: growing) | 76.26% | 33.63% | Compare |
| CBLL CeriBell, Inc. | $1.0B | — (loss-making) | — (loss-making) | +29.89% (above 0%: growing) | n/m | −19.65% (below 0%: shrinking) | 89.77% | (70.03%) | |
| AHCO AdaptHealth Corp. | $1.0B | — (loss-making) | — (loss-making) | +10.90% (above 0%: growing) | n/m | −23.58% (below 0%: shrinking) | 15.40% | (20.91%) | Compare |
| BVS Bioventus Inc. | $899.9M | 12.3× | 17.2× | +2.73% (above 0%: growing) | +100.60% (above 0%: growing) | −31.40% (below 0%: shrinking) | 68.19% | 6.81% | Compare |
| QDEL QuidelOrtho Corporation | $880.5M | — (loss-making) | — (loss-making) | −11.57% (below 0%: shrinking) | n/m | +120.70% (above 0%: growing) | 46.79% | (1.21%) | Compare |
| BBNX Beta Bionics, Inc. | $842.1M | — (loss-making) | — (loss-making) | +30.28% (above 0%: growing) | n/m | −45.46% (below 0%: shrinking) | 57.26% | (74.94%) | Compare |
| Median of peers | $1.1B | 44.9× | 26.0× | +12.53% | — | +8.51% | 61.77% | (4.51%) |
Pay and ownership Proxy statement filed 20 April 2026
Ownership
Directors and executive officers, together
17.70%
Entities affiliated with The Rise Fund Clearthought L.P.
10.50%
Entities affiliated with FMR LLC
10.40%
Juliet Tammenoms Bakker
6.60%
Entities affiliated with Longitude Venture Partners IV, L.P.
6.50%
Entities affiliated with The Global Value Investment Portfolio Management Pte Ltd.
6.30%
Entities affiliated with Red Tree Venture Fund, L.P.
5.80%
Josef Parvizi, M.D., Ph.D.
5.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement